SEC EDGARAUG 132 min read$GKOS

Gilliam Joseph E sold $10.8M of GKOS

Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.

Original reporting

SEC EDGAR · Gilliam Joseph E

Published Aug 13, 2026, 11:57 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 13, 2026, 11:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$GKOS

Neutral

medium confidence

Mentioned

$GKOS

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$GKOSNeutralLow

Why it matters

The newest disclosed fact is the open-market sale of 60,000 shares on 2026-08-11 at $178.8900 to $180.4900, with holdings after the sale of 72,588 shares.

Market read

Traders may briefly reassess sentiment around GKOS due to insider selling, but there is no accompanying operational or financial catalyst in the text.

What to watch

Insider sales can be driven by diversification, pre-planned personal needs, or option/RSU mechanics not captured here; traders should check for other recent insider activity and any concurrent company news.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-13 after trades dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by its President and COO.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GKOSNeutralMedium confidence

Context

Form 4 shows GKOS COO sold 60,000 shares in open-market transactions totaling about $10.78M at ~$179.74 average.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader news flow.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and pricing, but it does not include new guidance, contracts, or regulatory/clinical catalysts.

Market effects

Sector

No clear sector read-through from a single insider sale without additional company-specific developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, especially since it is not stated as part of a 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

issuer
GLAUKOS Corp
Company whose insider transaction is disclosed via Form 4.
insider
Gilliam Joseph E
President and COO who sold 60,000 shares in open-market transactions.

Read at source ← All news

AUG 25

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min

AUG 20

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min

AUG 20

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min

AUG 8

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min

JUL 31

$GKOSMed

H.C. Wainwright raises Glaukos stock price target on strong results

H.C. Wainwright raised its Glaukos (NYSE:GKOS) price target to $195 from $168 and kept a Buy rating after Glaukos reported Q2 2026 results. Revenue was $185.6M, up 49.5% YoY, and glaucoma revenue was $155.2M. Glaukos raised full-year 2026 net sales guidance to $680M-$700M.

investing.com4 min

JUL 30

$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min